The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

Publication | Closed Access

DOI

102

Citations

References

2005

Year

Evangelos Terpos, Dimitra Mihou, Richard Szydlo, K Tsimirika, Christos Karkantaris, Marianna Politou, Ersi Voskaridou, Amin Rahemtulla, Meletios Α. Dimopoulos, Konstantinos Zervas

Leukemia

Bone DiseaseHematological MalignancySrankl/osteoprotegerin RatioRefractory/relapsed Multiple MyelomaHematologyPharmacotherapyIntermediate DosesMedicineRadiation OncologyOsteoporosisOrthopaedic SurgeryHealth Sciences